Efficacy of Ultrasound-Guided PRP Versus Corticosteroid Injection in Patients With Ulnar Neuropathy at Elbow

Tanta University

Status and phase: Completed; Phase 3; Phase 2

Conditions: Ulnar Neuropathy at Elbow

Treatments: Drug: PRP; Drug: Triamcinolone Acetonide 40mg/mL

Study type: Interventional

Funder types: Other

Identifiers

NCT05567081

34743/6/21

Details and patient eligibility

About

This study was be performed on 60 patients with ulnar neuropathy at elbow diagnosed clinically and by electrophysiology and/or ultrasonography selected from Physical medicine, Rheumatology & Rehabilitation Department, Faculty of Medicine, Tanta University.

Patients were be randomly divided into 2 groups:

Group I: will undergo a single ultrasound-guided deep perineural injection with 3ml PRP at the thickest part of the ulnar nerve. PRP will be prepared by PRP method.

Group II: will undergo a single ultrasound-guided deep perineural injection with 1ml corticosteroid (triamcinolone acetonide, 40mg/mL) mixed with 1ml lidocaine hydrochloride.

Enrollment: 60 patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients with ulnar neuropathy at elbow diagnosed clinically and by electrophysiology and/or ultrasonography.

Exclusion criteria

1. Patients with severe ulnar neuropathy at elbow according to Gu's classification. 15

2. Brachial plexopathy, peripheral neuropathy, and cervical radiculopathy.

3. History of recent elbow trauma or operation.

4. Malignant neoplasm.

5. Pregnancy.

6. Bleeding Disorders.

7. Factors affecting nerve healing process e.g., tobacco use and systemic corticosteroid administration.

8. Contraindications for PRP injection:

   1. Significant renal or hepatic dysfunction.
   2. Critical thrombocytopenia.
   3. Hemodynamic instability.
   4. Septicemia.
   5. Local infection at the site of the procedure.
   6. Consistent use of nonsteroidal anti-inflammatory drugs within the last two weeks.
   7. Local injection at the suspected treatment site within the last month.
   8. Recent fever or illness.
   9. Hemoglobin level <10 g/dL.
   10. Platelet dysfunction disorders.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

60 participants in 2 patient groups

PRP group

Experimental group

Description:

3 cm of autologous platelet rich plasma injected once around the thickest part of ulnar nerve.

Treatment:

Drug: PRP

Corticosteroid group

Experimental group

Description:

Triamcinolone Acetonide 40mg/mL (1ml) mixed with 1ml lidocaine hydrochloride injected once around the thickest part of ulnar nerve.

Treatment:

Drug: Triamcinolone Acetonide 40mg/mL